A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Key facts

Sponsor

Tasly GeneNet Pharmaceuticals Co., Ltd

Principal Investigator

Rui Liu

Tasly Group,Co.Ltd.

Intervention

PXT3003(drug)

Enrollment

176 enrolled

Eligibility

16-65 years · All sexes

Timeline

2021 – 2024

Study locations (25)

• Peking University Third Hospital, Beijing, China
• Xuanwu Hospital Capital Medical University, Beijing, China
• The First Bethune Hospital of Jilin University, Changchun, China
• The Third Xiangya Hospital of Central South University, Changsha, China
• The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
• Nanfang Hospital Southern Medical University, Guangzhou, China
• The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, China
• The Affiliated Hospital of Guizhou Medical University, Guiyang, China
• The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
• The First Affiliated Hospital of Harbin Medical University, Harbin, China
• The First Affiliated Hospital of Anhui Medical University, Hefei, China
• Inner Mongolia People's Hospital, Hohhot, China
• Qilu Hospital of Shandong University, Jinan, China
• The Second Affiliated Hospital of Nanchang University, Nanchang, China
• The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
• +10 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Autosomal recessive Charcot-Marie-Tooth disease type 2X

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07461896
  Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
  Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

See all trials for Autosomal recessive Charcot-Marie-Tooth disease type 2X →